# Geneos Therapeutics

> Geneos Therapeutics is a clinical-stage biotherapeutics company in Plymouth Meeting / Philadelphia, Pennsylvania, building DNA-based personalized immunotherapies for cancer. Its proprietary GT-EPIC platform reads a patient's own tumor mutations and manufactures a custom DNA plasmid vaccine encoding up to 40 of that patient's unique neoantigens, delivered intradermally with an IL-12 cytokine adjuvant and electroporation. In 2024 the company published Phase 1/2 GT-30 data in Nature Medicine showing its vaccine plus pembrolizumab generated new neoantigen-specific T cells and clinical responses in advanced liver cancer - billed as the first definitive demonstration of a personalized cancer vaccine boosting response to anti-PD-1 therapy.

- **Founded:** 2016
- **Headquarters:** Plymouth Meeting, Pennsylvania, United States
- **Founders:** Niranjan Y. Sardesai (Founder, President & CEO)
- **Team size:** ~13 employees
- **Products:** GT-EPIC platform, GNOS-PV02, GT-30 clinical program, CELLECTRA intradermal delivery
- **Notable:** Published Phase 1/2 GT-30 results in Nature Medicine (2024), described as the first definitive demonstration of a personalized cancer vaccine enhancing clinical response to anti-PD-1 therapy., Induced new vaccine-encoded neoantigen-specific T cell responses in 14 of 14 (100%) evaluated patients., Reported complete responses in second-line advanced hepatocellular carcinoma, a notoriously hard-to-treat cancer.

## Products & services

- **GT-EPIC platform** — Proprietary DNA-based platform that identifies a patient's tumor neoantigens and designs a custom immunotherapeutic DNA plasmid encoding up to 40 of them (up to 80 by combining two plasmids).
- **GNOS-PV02** — Personalized therapeutic cancer vaccine candidate; a DNA plasmid encoding patient-specific neoantigens, co-delivered with a DNA-encoded IL-12 cytokine adjuvant.
- **GT-30 clinical program** — Phase 1/2 study of GNOS-PV02 plus IL-12 and pembrolizumab in second-line advanced hepatocellular carcinoma (liver cancer); 36 patients, single-arm, open-label, multi-center.
- **CELLECTRA intradermal delivery** — Electroporation-based intradermal delivery (device technology licensed from Inovio) used to drive the DNA vaccine into skin tissue and prime the immune response.

## Achievements

- Published Phase 1/2 GT-30 results in Nature Medicine (2024), described as the first definitive demonstration of a personalized cancer vaccine enhancing clinical response to anti-PD-1 therapy.
- Induced new vaccine-encoded neoantigen-specific T cell responses in 14 of 14 (100%) evaluated patients.
- Reported complete responses in second-line advanced hepatocellular carcinoma, a notoriously hard-to-treat cancer.
- Demonstrated the ability to encode up to 40 neoantigens per DNA plasmid (up to 80 by combining two).
- Raised roughly $60M to advance its personalized immunotherapy pipeline.

## Latest updates

- **2024-04** — Announced positive Phase 1/2 GT-30 data for its personalized therapeutic cancer vaccine, published in Nature Medicine.
- **2023-09** — Closed Series A3 financing with an additional $5M investment, including participation from Shanghai Healthcare Capital.
- **2022-11** — Reported another complete response in its ongoing trial of personalized cancer vaccination in second-line advanced liver cancer.
- **2021-03** — Secured $12M Series A1 led by KIP Global Bio Fund with Sante Ventures and Inovio.

## Links

- Website: https://geneostx.com
- LinkedIn: https://www.linkedin.com/company/geneos-therapeutics

---

Profile page: https://yespress.io/geneos-therapeutics
Published by YesPress — https://yespress.io
Last updated: 2026-06-10